Women Healthcare Market Research Report Information By Indication(Postmenopausal Osteoporosis, Infertility, Reproductive Health Management, Polycystic Ovary Syndrome, Gynecologic Cancer, And others), By Diagnosis and Treatment (Bone Densitometry, Diagnostic Imaging Tests, Biopsies, Ovulation Testing, And Others), By Treatment (Therapeutics, Surgeries, And Others), By End Users (Hospitals & Clinics, Gynecology Centers, Research Institutes, And Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Foreca

Global Women Healthcare Market Overview

Women Healthcare Market was valued at USD 17.1 billion in 2023 and is projected to grow from USD 18.6 billion in 2024 to USD 34.21 billion by 2032, exhibiting a CAGR of 8.90% during the forecast period (2024 - 2032). Rising frequency of chronic health conditions, increasing women’s biological issues, and advanced treatment are the key market drivers enhancing the market growth.

 Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Women Healthcare Market Trends

• Growing Prevalence of women’s biological issues to boost market growth

The women’s healthcare market is concentrated on women’s health problems. The market deals with issues such as pregnancy, menopause, breast cancer, and conditions related to reproductive organs. The growing biological issues in women's also driving the market growth. For instance, According to World Health Organization (WHO), breast cancer is frequently occurring among women, affecting 2.1 Billion women every year, and about 15% of all women deaths are due to breast cancer.

Further, advanced treatment and new technologies are also enhancing market growth. For Instance: Mexico-based Higia Tech is producing a breast cancer detection bra, EVA, that connects to a mobile app. The bra is used to recognize a person’s individual level of risk for breast cancer by measuring the surface of the breast & surrounding areas, taking into account details such as color, texture, and temperature.

Additionally, according to World Health Organization (WHO), in 2020, 685,000 people worldwide died and 2.3 billion women were diagnosed with breast cancer. The most common disease in the globe as of the end of 2020 was breast cancer, which had been diagnosed in 7.8 billion women in the previous five years. Worldwide, breast cancer causes more lost disability-adjusted life years (DALYs) for women than any other kind of cancer. Every country in the globe experiences breast cancer in women after puberty at any age, albeit the incidence rates rise as people age. Therefore, such medical condition related to the women’s health has enhanced the  market CAGR of women healthcare across the globe in the recent years.

Women Healthcare Market Segment Insights

Women Healthcare Indication Insights

The market segments of women healthcare, based on indication type, includes postmenopausal osteoporosis, infertility, reproductive health management, polycystic ovary syndrome, gynecologic cancer, and others. The postmenopausal osteoporosis segment held the majority share in 2022, contributing to the Women Healthcare Market revenue. This is primarily owing to the rising prevalence of postmenopausal osteoporosis, the main focus of pharmaceutical companies providing drugs for postmenopausal osteoporosis, and the increasing risk of osteoporosis fractures supported the growth of this segment across the globe.

October 2021: The phase III clinical research program OASIS, launched by Bayer, intended to assess the effectiveness and safety of elinzanetant for the treatment of vasomotor symptoms during menopause.

Women Healthcare Diagnosis Insights

The Women Healthcare Market segmentation, based on diagnosis, includes Bone Densitometry, Diagnostic Imaging Tests, Biopsies, Ovulation Testing and others. The ovulation testing segment dominated the market in 2022, and bone densitometry segment is projected to be the faster-growing segment during the forecast period, 2024-2032. For Instance: Some of the most common issues of infertility are endometriosis, polycystic ovarian syndrome (PCOS), and ovulation issues. The World Health Organization (WHO), estimates that in 2021, endometriosis will affect over 190 billion women worldwide who are of reproductive age. Hence, rise of ovulation testing and bone densitometry for women healthcare positively impacts the market growth.

Women Healthcare Treatment Insights

The Women Healthcare Market data has been bifurcated by treatment into therapeutics, surgeries, and others. The therapeutics segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030.

May 2018: Ava Science (Switzerland), women may get a thorough look at nine health factors that can be assessed to improve or prevent conception using  the ovulation sensor bracelet and associated mobile app. These health factors are measuered while a woman is sleeping and used to forecast her next fertile window, include metrics like breathing rate and skin temperature.

Figure 1: Women Healthcare Market, by Treatment, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Women Healthcare End User Insights

Based on End Users, the global women healthcare industry has been segmented into hospitals & clinics, gynecology centers, research institutes, and others. The Research institute segment is dominating the market in 2022. Due to innovation and the development of products and technologies are the main factor of the market’s growth. The gynecology centers is the fastest- growing segment in the women healthcare industry in the coming years.

 January 2022: The women’s hospital at Jackson Memorial, AdventHealth Celebration, and HCA Florida Healthcare’s Medical Center using the Robotic surgical technology, Homins surgical system by Memic Innovative Surgery for gynecological procedures.

Women Healthcare Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Women Healthcare market accounted for USD 3.48 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This is attributed due to the increasing awareness regarding the availability of diagnostic tests & treatments, a well-established healthcare infrastructure, and developed reimbursement coverage across the region.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: WOMEN HEALTHCARE MARKET SHARE BY REGION 2023 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe women healthcare market accounts for the second-largest market share due to the availability of cutting-edge treatment facilities, government backing for the growth of the women healthcare industry, an ageing population, and an increase in incidence of breast cancer. Further, the Germany market of women healthcare held the largest market share, and the UK market of women healthcare was the fastest growing market in the European region.

The Asia-Pacific women healthcare Market is expected to grow at the fastest CAGR from 2024 - 2032. This is due to increased rates of miscarriages, abortions and the government initiative towards women health awareness. Moreover, China market of women healthcare held the largest market share in the Asia-Pacific region.

India market of women healthcare is the fastest growing market in the coming years. For instance, the National Coordination Committee organized the Jan Swasthya Abhiyan for the wellbeing of women in the country. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2022–2030.

Women Healthcare Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of Women Healthcare grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the women healthcare industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global women healthcare industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, women healthcare industry has provided medicine with some of the most significant benefits. The women healthcare market major player such as Allergan plc. (Ireland), Amgen (California), Bayer AG (Germnay), Becton Dickinson and Company (U.S.), Eli Lilly Company (U.S.), Merck & Co. Inc. (U.S.), Pfizer Inc., Teva Pharmaceuticals (Israel) and others are working to expand the market demand by investing in research and development activities.

 Pfizer Inc. is a multinational pharmaceutical and biotechnology company. Pfizer produces and develops vaccines and medicines for oncology, endocrinology, immunology, cardiology, and neurology. The company’s vision is we are in relentless pursuit of breakthroughs that change patients’ lives. For instance: The Food an d Drug Administration(FDA) has given the thumbs-up to Myovant Sciences and Pfizer Inc.’s MYFEMBREE, the first once-daily medication for managing of heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration of upto 24 months.

Key Companies in the market of Women Healthcare includes

• Allergan plc. (Ireland)


• Amgen (California)


• Merck & Co. Inc. (U.S.)


• Bayer AG (Germany)


• Becton Dickinson and Company (U.S.)


• Eli Lilly Company (U.S.)


• Pfizer Inc.


• Teva Pharmaceuticals (Israel), among others

Women Healthcare Industry Developments

September 2022: Lynparza was given clearance in China as the first line of maintenance therapy with bevacizumab for advanced ovarian cancer with homologous recombination deficit (HRD) positivity.

April 2021: Mayne Pharma and Mithra Pharmaceuticals Group Limited declared the approval of oral contrace[ptive NEXTSTELLIS by the U.S. Food and Drug Administration (FDA). It is the only contraceptive pill having estetrol which is manufactured from a plant source.

Women Healthcare Market Segmentation

• Postmenopausal Osteoporosis


• Infertility


• Reproductive Health Management


• Polycystic Ovary Syndrome


• Gynecologic Cancer


• Others

Women Healthcare Diagnosis Outlook

• Bone Densitometry


• Diagnostic Imaging Tests


• Biopsies


• Ovulation Testing


• Others

Women Healthcare Treatment Outlook

• Therapeutics


• Surgeries


• Others

Women Healthcare End User Outlook

• Hospitals & Clinics


• Gynecology Centers


• Research Institutes


• Others

Women Healthcare Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America